Enanta Pharmaceuticals, Inc. ENTA
Updated: 10 Aug 2026
No signal published yet
We already track Enanta Pharmaceuticals and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Enanta Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Enanta Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 18, 2026, Enanta announced the advancement of its zelicapavir program for respiratory syncytial virus into a registrational Phase 2b/3 trial following an End-of-Phase 2 meeting with the U.S. FDA. On June 23, 2026, partner AbbVie received European Commission approval for MAVIRET to treat acute hepatitis C virus.
What Firelda Watch includes for Enanta Pharmaceuticals, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Enanta Pharmaceuticals, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Enanta Pharmaceuticals free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more